Andrew Cooper's questions to Neogenomics Inc (NEO) leadership • Q1 2025
Question
Andrew Cooper of Raymond James asked for a reminder of the hurdles for achieving operational readiness for the RaDaR 1.1 MRD test and the stage gates for its commercial launch. He also inquired about the P&L trajectory for R&D and Sales & Marketing expenses for the remainder of the year.
Answer
CIO Andrew Lukowiak outlined two main focus areas for RaDaR 1.1 readiness: completing bridging studies to transfer reimbursement claims from version 1.0, and exercising the 'operational muscle' to ensure systems and commercial teams are prepared. CFO Jeff Sherman projected that sales and marketing expenses will continue to grow with revenue and incremental hires, while R&D expense, which was higher in Q1 due to validation work, will likely decrease slightly as the year progresses.